Clinical Trial

A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-27; most recent amendment 2026-05-25.
Status change: Recruiting → Active, Not Recruiting 2026-05-25
Status change: Not Yet Recruiting → Recruiting 2025-05-23
Trial Details
NCT Number NCT06908876
Lead Sponsor Innovent Biologics Technology Limited (Shanghai R&D Center)
Conditions Diabetic Macular Oedema
Enrollment 150 participants
Start Date 2025-04-24
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-27